INTUITIVE Q3 2026 Earnings Release - INTUITIVE SURGICAL INC

Financial Performance:

• Total revenue grew 22% year-over-year to just over $3 billion, with 84% classified as recurring revenue.
• Non-GAAP earnings per share increased 25% to $3.00; GAAP EPS was $1.49, negatively impacted by a one-time $450 million litigation settlement.
• Non-GAAP operating margin was 42% of revenue (41% excluding a $28 million one-time tariff refund).
• Non-GAAP gross margin reached 69.9%, up from 68.0% in the prior year, reflecting product cost reductions and fixed overhead leverage.
• Net DaVinci placements grew 40% to 546 systems, with 315 DaVinci 5 units placed.
• Service revenue increased 22% to $482 million, driven by a growing installed base and higher mix of DaVinci 5.
• Company ended the quarter with $6.8 billion in cash and investments, down from $8.6 billion due to $2.9 billion in stock repurchases.
• Revenue per procedure (I&A) for DaVinci was approximately $1,860, up from $1,800, driven by product mix despite upcoming pricing actions.

Guidance and Future Outlook:

• Full-year 2026 procedure growth forecast narrowed to 14%–15% (previously 13.5%–15.5%), expected closer to the midpoint.
• 2026 non-GAAP gross profit margin guidance updated to 68.3%–68.7% of revenue (previously 68%–69%), factoring in 90 basis points of tariff impacts.
• 2026 non-GAAP operating expense growth expected at 11%–13%, with R&D growing faster than SG&A.
• New extended use program (EUP) and China pricing reductions expected to lower I&A revenue per procedure by 3%–5% on a mixed constant basis, with full implementation expected by the end of 2027.
• Non-GAAP other income (interest) forecast between $300 million and $310 million.
• Company plans to update its long-term opportunity estimate for soft tissue surgery in January 2027.

Business Segments and Product Lines:

• Total procedures increased 15%, with DaVinci procedures up 14% and Ion procedures up 31%.
• DaVinci 5 and SinglePort (SP) accounted for 65% of global system placements; DaVinci 5 utilization exceeded the Xi base.
• SP procedures grew 55% globally (50% in U.S., 40% in Korea), with 487 SP systems installed across 27 countries.
• XIR placements more than doubled; 18 systems installed in U.S. ASCs, signaling growth in ambulatory settings.
• New clearances received for cardiac procedures (DaVinci 5), transvaginal gynecological procedures (SP), and force feedback instrumentation.
• Regulatory submissions made for SP vessel sealer (Q4) and cavitational ultrasonic aspirator for liver/pancreas.
• Next-generation flexible robotic endoscope for GI tract received FDA 510K clearance, though early in development.
• Reimbursement secured for Ion in Korea; CE marks obtained for force feedback and cardiac procedures.

Market and Competitive Landscape:

• International growth was robust with 20% total procedure growth; OUS DaVinci placements rose 29%.
• Benign procedure adoption accelerated significantly outside the U.S., growing 41% in Q3, led by hernia repairs and cholecystectomy.
• Market focus in Asia on Japan and India, where India surpassed 200,000 cumulative procedures with 42% growth; China faces a challenging operating environment.
• Intuitive announced a new manufacturing facility in Penang, Malaysia, to begin operations in 2028 to support Asia growth.
• Management notes that competitors (e.g., Stryker) are offering modular systems for ASCs, but Intuitive maintains a cart-based architecture strategy.
• Over 7,000 customers in 70+ countries performed procedures, totaling over 10,000 procedures daily.

Risks and Challenges:

• Pricing headwinds from extended use programs and China policy changes expected to reduce I&A revenue per procedure by 3%–5% over time.
• Regulatory and reimbursement uncertainty in China affecting capital placements and procedure growth.
• Potential impacts from lower ACA enrollment, Medicaid eligibility changes, and 340B program shifts in the U.S.
• Input cost inflation in freight and semiconductor memory partially offsetting cost reduction programs.
• Litigation settlement regarding third-party remanufacturing and servicing, pending court approval, created a one-time GAAP charge.

Management Commentary and Tone:

• Tone was confident and strategic, emphasizing "durable growth" through innovation, clinical evidence, and expanded access rather than just short-term revenue maximization.
• Management highlighted a shift in customer behavior toward data-driven decision-making, with large IDNs creating real-time dashboards comparing robotics to laparoscopy and open surgery.
• CEO emphasized that the "quintuple aim" (better outcomes, experience, care team, cost, and access) drives the strategy, particularly for benign procedures.
• CFO confirmed the 3%–5% pricing headwind is intentional to broaden the addressable market, expecting volume elasticity to offset the revenue per procedure decline over time.

Analyst Questions and Answers:

• U.S. Procedure Growth: Analysts questioned the 10% U.S. growth rate; Management attributed it to the difficult prior-year comparison and emphasized that capacity expansion, ASC focus, and new indications will drive future acceleration.
• Pricing and Elasticity: Clarified that the 3%–5% revenue headwind will be partially offset by higher-mix products (DaVinci 5, SP) and that volume elasticity is expected to materialize gradually through 2027.
• Pipeline and Innovation: Discussed upcoming Ion developments (ROSE cytology, endobronchial ultrasound) and DaVinci advancements (hyperspectral imaging, AI features) expected to drive accretive revenue per procedure.
• ASC Strategy: Reiterated preference for cart-based architecture over modular systems for ASCs, citing reliability and ecosystem requirements, with a focus on IDN-affiliated ASCs.
• Litigation Settlement: Confirmed the settlement provides certainty for customers regarding third-party instruments and services, strengthening long-term relationships.

Other Key Points:

• Over 48,000 peer-reviewed publications support the da Vinci platform; the "Benign COMPARE" study meta-analysis of 1.5 million patients showed lower conversion rates and shorter hospital stays compared to laparoscopy and open surgery.
• Telepresence adoption is increasing, serving as a foundation for future telesurgery regulatory clearances expected in H1 2028.
• No contribution to the Intuitive Foundation is expected in 2026, following a $70 million multiyear contribution made in late 2025.
• Management plans to update long-term opportunity estimates in January 2027 following significant OUS investments and expansion into new geographies.